Agilent is Empowering the Fight Against Cancer

AACR Media Event

New Orleans / April 10, 2022

Sam Raha

President, Diagnostics and Genomics Group

Agilent Technologies



Agilent

Trusted Answers

2021 Summary: **Agilent Technologies**

$6.3B
FY21 Revenue

+15%
FY21 Core Rev. Growth (1)(2)

25.5%
FY21 Operating Margin (1)

+32%
FY21 EPS Growth (1)

Serving **customers** in over **100 countries**,

in over **250,000** research and diagnostics **labs**

~8%
of revenue
Invested in R&D yearly

Global Footprint (3)



(1) Presented on a non-GAAP basis, reconciliations to closest GAAP equivalent provided
(2) Core growth is reported growth adjusted for the effects of acquisitions and FX

A leading lab partner with unsurpassed capabilities and scale

Agilent's **Mission** and **Market Focus**

A global, collaborative team, serving vital industries in 6 key markets

Pharma & Biopharma

Clinical & Diagnostics



Academia & Government

Our Mission

Advancing the **quality of life**, by providing **trusted answers**

Environmental Analysis & Forensics

Food Safety & Authentication

Chemicals & Energy

Committed to

Accelerating the **advancement of science**

Providing complete, **integrated solutions**

Championing our **customers' success**

Cancer is a **strategic focus** for Agilent

Cancer facts

- As a scientific and medical community, we are making progress in understanding and managing cancer.
- Continued increase in incidence.
- 1 in 2 women, and 1 in 3 men in the US will develop cancer within their lifetime.
- Growing importance of biomarkers.
- Growing importance of NGS and multi-modality.

Agilent long range strategy

- Supporting cancer research, diagnosis and treatment is a priority focus area for Agilent; reaffirmed in our long-range strategy analysis.
- Committed to leveraging our broad portfolio of analytical instruments and technologies, our cancer experience and expertise along with our global reach and capabilities to serve cancer focused customers around the world.

Customer Focus

- Agilent serves the following cancer customer segments

R&D and Translational Research

Dx Test Developers

Dx Testing Labs

Agilent
Trusted Answers

Serving

R&D and Translational Research

Customers

Genomics solutions that enhance the **understanding** of the **underlying biology** and **mechanisms of cancer**

Workflow Integration

Sample	QC	Automation	Assays and Reagents			Sequencing	Analysis Reporting
								
All sample types	Tapestation	Magnis	Bravo	SureSelect Custom	SureSelect Cancer CGP	Exome V8 Methylation		Alissa Interpret

Market leading genomics QC instruments that are leveraged across all sample types

Market leading NGS chemistry cited in over 10,000 cancer publications

Automation that enables reproducibility and throughput across small and large labs

Enabling integrated workflows from sample QC through data analysis and interpretation

Cellular Analysis: enabling a revolution in cancer research

Cellular Analysis | Genomics | Biomarkers | Diagnostics | Companion Diagnostics | Biologics

A comprehensive portfolio of cancer cell biology research solutions

Seahorse



Detect and Characterize Metabolic Reprogramming Of Cancer Cells
Seahorse XF Analyzers

ACEA



Quantitative Immunophenotyping and Proliferation Assays
Novocyte Flow Cytometers

ACEA



Monitor Immune-Cell Killing In Real Time
xCELLigence RTCA Systems

BioTek

Real-Time Live Cell Imaging and High Content Screening
Cytation Cell Imaging Multi-Mode Readers

Agilent

Agilent 6495C Triple Quadrupole LC/MS

Uniquely enables the detection and quantitation of cancer neoantigens

- Cancer neoantigens are peptides from mutated genes which are presented on the cell surface by HLA.
- T-Cell recognition of neoantigens is the basis for immune cell killing of cancer cells.
- Numerous groups have been trying to target antibodies or cells to these tumor-specific epitopes, but due to their extremely low abundance the detection, validation, and quantitation have been daunting.
- Researchers at Johns Hopkins University (Bert Vogelstein's lab) developed a unique neoantigen detection and quantitation pipeline using the Agilent 6495C.
- The Valid NEO pipeline developed by Complete Omics has extended to the direct analysis of human-specific neoantigens from minute amounts of clinical research samples.



Cancer Neoantigen Detection on the 6495C Triple Quad

Agilent
Trusted Answers

Serving

Dx Test Developer

Customers

Leverage differentiated **genomics portfolio** to **support cancer Dx test development** *powered by Agilent*

Library Preparation

Providing industry leading target-enrichment chemistry, and foundational assays; Human Exome, SureSelect Cancer CGP

Enrichment Panels

Assay design service to support optimized turnaround and performance for lab developed tests (LDTs) customers

Automation



Automation portfolio to support robust, reproducible testing for any throughput

QC

Supporting customers in the Americas, Europe and Asia to gain regulatory clearance for their testing solutions

For Research Use Only. Not for use in diagnostic procedures.

Agilent
Trusted Answers

Serving

Dx Testing Lab

Customers

A leading supplier for **Pathology labs** performing **cancer Dx**



Improving customer experience by leveraging high-throughput Dako Omnis advanced staining platform and menu expansion

Enabling **cancer Dx** in partnership with Biopharma



Fully automated

Ki67 IHC MIB-1 assay on Dako Omnis

1st PD-L1 companion diagnostic approved: PD-L1 IHC 22C3 pharmDx

7 total FDA-approved indications for PD-L1 IHC 22C3 pharmDx

88 countries with access to an Agilent PD-L1 diagnostic kit

Tens of thousands

of Agilent PD-L1 diagnostic kits distributed globally

Over 1 million

patient treatment decisions informed by Agilent PD-L1 diagnostic kits

Delivering on the **promise** of **precision medicine**

Leveraging relevant technologies to enable multi-modal diagnostic analysis

Featured detection technologies are treated in bold

SOURCE MATERIAL:
Cellular Protein

DETECTION TECHNOLOGY:
Immunohistochemistry (IHC), Immunoblotting, ELISA, Liquid Chromatography-Mass Spectrometry (LC-MS)

SOURCE MATERIAL:
RNA

DETECTION TECHNOLOGY:
RNA-ISH, Reverse Transcription PCR, Quantitative PCR (qPCR), RNA-seq, Digital PCR (dPCR), RNA Microarray

SOURCE MATERIAL:
Circulating Tumor Cells

DETECTION TECHNOLOGY:
Flow Cytometry

SOURCE MATERIAL:
Circulating Tumor DNA

DETECTION TECHNOLOGY:
NGS, qPCR, dPCR

SOURCE MATERIAL:
Genomic DNA

DETECTION TECHNOLOGY:
FISH, Sanger Sequencing, NGS, qPCR, dPCR, Array Comparative Genomic Hybridization, ChIP-on-chip Microarray



Note: Technologies listed may not be approved for diagnostic use.

NGS based **liquid biopsy** capability added via **Resolution Bioscience**

Agilent to Acquire Resolution Bioscience,
Strengthening Leadership Position in Cancer Diagnostics

Highlights:

- Resolution Bioscience is a fast-growing, innovative leader in next-generation sequencing (NGS)-based oncology solutions.
- Combination brings together Resolution Bioscience's noninvasive liquid biopsy platform that improves cancer diagnostics with Agilent's leadership in tissue-based companion diagnostics and global commercial and regulatory scale.
- Furthers Agilent's participation in fast-growing NGS technologies for precision oncology, expanding Agilent's addressable market by $3 billion in 2025 with that figure estimated to double by 2030.

SANTA CLARA, Calif., March 2, 2021 – Agilent Technologies Inc. (NYSE: A), today announced it has entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions. The acquisition complements and expands Agilent's capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve

RESOLUTION BIOSCIENCE

RESOLUTION

res•o•lu•tion\ re-zə-'lü-shən\ **1.** determination after careful consideration, a solution. **2.** firm, unwavering adherence to purpose, resolve. **3.** sharp and extremely clear, detailed

WE BRING YOUR CANCER INTO FOCUS

ctDx™ the **Comprehensive** Liquid Biopsy Platform

The ctDx platform uses next-generation sequencing (NGS) and a standard peripheral blood sample. This non-invasive assay platform has been validated to detect all four major types of genetic alterations known to drive cancers. Turnaround time is measured in days, not weeks.



SNVs Indels Fusions CNV

Agilent Thought Leader Award Recipients – **Leading the Way in Cancer Research**

Perelman School of Medicine, University of Pennsylvania



Carl June
Michael Milone

Contributions to the field of CAR T-cell mediated cancer immunotherapy

Nov 2020

中国科学院 Chinese Academy of Sciences

Hua Liang Jiang

New targets for cancer therapy and designing inhibitors that block protein-protein interactions.

Sept 2019

UCLA

Antoni Ribas

Melanoma physician-researcher recognized for his research in cancer genomics and immunotherapy.

April 2019

VIB-KU Leuven Center for Cancer Biology

Diether Lamrechts

Translational cancer research using genomics and epigenomics approaches.

Feb 2019

中国科学院 Chinese Academy of Sciences

Jiandong Jiang

Adoption of genomics, metabolomics and integrated biology analysis to the study cancer and metabolic diseases.

July 2017

Memorial Sloan Kettering Cancer Center

Scott Lowe

Next generation CRISPR-based genetic screens to systematically identify and characterize novel targets for cancer therapeutics.

Oct 2016

University of Illinois Urbana-Champaign

Rohit Bhargava

Applications of spectroscopic imaging to biomedical sciences, inc. cancer biology and clinical applications.

Oct 2016

The Jackson Laboratory

Peter Robinson

Development of the Human Phenotype Ontology, a standardized vocabulary of phenotypic abnormalities encountered in human disease.

Feb 2016

Mount Sinai

Carlos Cordon-Cardo

Recognition of his groundbreaking work in molecular and translational pathology.

Sept 2014

institut Curie

Emmanuel Barillot

Dbase of cellular signaling pathways and tool to help pharma develop more effective cancer treatments.

Aug 2013

The University of Newcastle Australia

Carolyn Mountford

Nuclear magnetic resonance (NMR) spectroscopy technology in cancer research.

Apr 2013

TEXAS The University of Texas at Austin

Ronald DePinho

Characterization of alterations in metabolic flux in tumors. Biomarkers early detection pancreatic cancer.

Dec 2012

BROAD INSTITUTE

Steven Carr

Analysis of proteins and peptides, diagnose cardiovascular disease, breast cancer and ovarian cancer.

Oct 2011

Karolinska Institutet

Janne Lehtio

Quantitative proteomics methods development and cancer proteomics.

June 2010

Agilent

Agilent

Trusted Answers